Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMI1 | P35226 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 7/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797322 | 0.81 | ALDH1A1 (0.46) | BMI1ALDH1A1L3MBTL1DHODH | |
| SCHEMBL1708065 | 0.80 | TSHR (0.59) | TSHRALDH1A1L3MBTL1 | |
| SCHEMBL1708022 | 0.78 | ALDH1A1 (0.48) | BMI1TSHRPDE2APDE10AALDH1A1 | |
| SCHEMBL3792403 | 0.75 | BMI1 (0.35) | BMI1ALDH1A1L3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL1708124 | 0.75 | MAPK1 (0.48) | TSHRALDH1A1CYP1A2 | |
| SCHEMBL3796465 | 0.74 | BMI1 (0.34) | BMI1ALDH1A1 | |
| SCHEMBL1708381 | 0.73 | BMI1 (0.40) | BMI1TSHRL3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL1707938 | 0.71 | DHFR (0.39) | ALDH1A1PIK3C2B | |
| SCHEMBL3792099 | 0.71 | HSD17B10 (0.44) | ALDH1A1L3MBTL1DHODH | |
| SCHEMBL21621709 | 0.70 | PDCD1 (0.40) | TSHRALDH1A1HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | BMI1 2098/4885TSHR 637/4885PDE2A 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.